Maybe there are a lot of people who think the abiraterone data weren't SO good that OGX-011 plus generic taxotere won't have a place in the treatment mix of advanced PCa. It's worth taking a look at the OGX-011 phase II data from 2009.. 6.5 million shares outstanding, $45 million of cash. Three Phase III trials being funded by TEVA.
Market Data 
Markets 
AI
